Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group.

Thomas P Miller, S. Dahlberg

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The early results of the SWOG randomized trial indicate that there is no significant difference in outcome for patients treated with CHOP compared to m-BACOD, ProMACE-CytaBOM, and MACOP-B. However, a major feature of these latter regimens has been the durability of response, and consequently, further follow-up of the SWOG study is indicated. However, it is already clear that the magnitude of any difference that might be detected with further follow-up will be small and disproves some early predictions. In our view, much of the controversy regarding treatment for DLCL resulted from inappropriate comparisons of results of new studies to historic CHOP trials without regard for major differences in patient selection.

Original languageEnglish (US)
Pages (from-to)53-63
Number of pages11
JournalCancer Treatment and Research
Volume66
StatePublished - 1993

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Patient Selection
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{96204945ec1f4dcfaa8d21350a47a0a1,
title = "Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group.",
abstract = "The early results of the SWOG randomized trial indicate that there is no significant difference in outcome for patients treated with CHOP compared to m-BACOD, ProMACE-CytaBOM, and MACOP-B. However, a major feature of these latter regimens has been the durability of response, and consequently, further follow-up of the SWOG study is indicated. However, it is already clear that the magnitude of any difference that might be detected with further follow-up will be small and disproves some early predictions. In our view, much of the controversy regarding treatment for DLCL resulted from inappropriate comparisons of results of new studies to historic CHOP trials without regard for major differences in patient selection.",
author = "Miller, {Thomas P} and S. Dahlberg",
year = "1993",
language = "English (US)",
volume = "66",
pages = "53--63",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Treatment of diffuse large-cell lymphoma

T2 - a summary of outcome for patients treated by Southwest Oncology Group.

AU - Miller, Thomas P

AU - Dahlberg, S.

PY - 1993

Y1 - 1993

N2 - The early results of the SWOG randomized trial indicate that there is no significant difference in outcome for patients treated with CHOP compared to m-BACOD, ProMACE-CytaBOM, and MACOP-B. However, a major feature of these latter regimens has been the durability of response, and consequently, further follow-up of the SWOG study is indicated. However, it is already clear that the magnitude of any difference that might be detected with further follow-up will be small and disproves some early predictions. In our view, much of the controversy regarding treatment for DLCL resulted from inappropriate comparisons of results of new studies to historic CHOP trials without regard for major differences in patient selection.

AB - The early results of the SWOG randomized trial indicate that there is no significant difference in outcome for patients treated with CHOP compared to m-BACOD, ProMACE-CytaBOM, and MACOP-B. However, a major feature of these latter regimens has been the durability of response, and consequently, further follow-up of the SWOG study is indicated. However, it is already clear that the magnitude of any difference that might be detected with further follow-up will be small and disproves some early predictions. In our view, much of the controversy regarding treatment for DLCL resulted from inappropriate comparisons of results of new studies to historic CHOP trials without regard for major differences in patient selection.

UR - http://www.scopus.com/inward/record.url?scp=0027428231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027428231&partnerID=8YFLogxK

M3 - Article

C2 - 8102863

AN - SCOPUS:0027428231

VL - 66

SP - 53

EP - 63

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -